BWAY
Brainsway Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 ▲ BrainsWay released new clinical data demonstrating that its FDA-clea…
- Mar 11 ▲ BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY…
- May 13 ▲ BrainsWay reported Q1 2026 revenue of $15.5M (+35% YoY) and net inco…
- May 25 to Jun 2 ▼ 4 days of insider sells: $0.00 by 2 insiders
- Jun 15 ▼ 1 insider sell $0.00
- Jul 20 BTIG initiates
- Aug 31 ▼ Short interest jumps 33.1% to 208.1K
- Sep 8 FDA: BrainsWay Reports Promising Pilot Study Results in Patient…
- Sep 30 ▼ Short interest jumps 25.5% to 250.5K
- Oct 19 Contract: BrainsWay Announces Strategic Collaboration with Inland Ps…
- Nov 2 Contract: BrainsWay Announces Strategic Collaboration with Mindful H…
- Nov 10 ▲ Brainsway reported Q3 2026 revenue of $18.1M, up 34% YoY from $13.5M…
Signal stack
Where each data set points today.
- InsidersMIXED
No open-market sales.
- InstitutionsMIXED
Q2 2026: 5 added (0 new), 5 trimmed or exited.
- AnalystsBULLISH
6 of 7 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate $0.087 → $0.087 over 90 days.
- Short sellersSTEADY
Short interest −11.8% to 199.4K shares. 2.5 days to cover, ≈0.5% of shares.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $2.9M |
| ARK Investment Management LLC | TRIM | $2.2M |
| SEI INVESTMENTS CO | TRIM | $1.9M |
| JPMORGAN CHASE & CO | DOUBLED | $1.5M |
| Tidal Investments LLC | DOUBLED | $1.4M |
| CITADEL ADVISORS LLC | TRIM | $737.0K |
| Trexquant Investment LP | TRIM | $572.2K |
| NewEdge Advisors, LLC | DOUBLED | $292.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
7 analystsPrice is below the lowest target. Median implies +103%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 10, 2026 | BTIG REITERATE | Buy |
| Sep 8, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 31, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 13, 2026 | Ladenburg Thalmann MAINTAIN | Buy |
| Aug 12, 2026 | BTIG MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Moiseyev Gilad Chief Technology Officer Jun 15, 2026 | SELL | 5,000 sh |
Roth Yiftach Chief Scientist Jun 2, 2026 | SELL | 1,000 sh |
Roth Yiftach Chief Scientist Jun 2, 2026 | SELL | 2,000 sh |
Roth Yiftach Chief Scientist Jun 1, 2026 | SELL | 2,000 sh |
Mitrany Rayten Michal Ety Director May 26, 2026 | SELL | 7,980 sh |
Mitrany Rayten Michal Ety Director May 25, 2026 | SELL | 10,000 sh |
Moiseyev Gilad Chief Technology Officer May 25, 2026 | EXERCISE | 7,500 sh |
Moiseyev Gilad Chief Technology Officer May 25, 2026 | TAX W/H | 1,902 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.09 | $0.07–$0.12 | +0.0% | $19.0M |
| Next Q | $0.11 | $0.09–$0.14 | +0.0% | $19.6M |
| Current FY | $0.25 | $0.25–$0.25 | -18.5% | $69.8M |
| Next FY | $0.50 | $0.37–$0.75 | -1.3% | $85.8M |
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 7 press releases · 8 bullish · 0 bearish · 9 neutral- BULLISH 6-KNov 10, 2026
Brainsway reported Q3 2026 revenue of $18.1M, up 34% YoY from $13.5M, and net income of $2.2M vs…
Revenue and earnings both grew strongly YoY with accelerating operating leverage. The 2026 financial guidance targets revenue growth of 30-34% with OPEX growth under 18%, implying continued margin…
- NEUTRAL 6-KNov 10, 2026
BrainsWay reported Q3 2026 revenue of $18.1M (+34% YoY) and diluted EPS of $0.05, below the…
The EPS miss against consensus is notable, but strong revenue growth, expanding margins, and robust cash flow may offset. Watch for full-year 2026 guidance update on the conference call and any…
- NEUTRAL 6-KNov 2, 2026
BrainsWay announced a strategic collaboration with Mindful Health Solutions (MHS), a behavioral…
Monitor for future revenue contributions from the MHS collaboration and the Heading Health investment, as well as any updates on the adoption of the SWIFT protocol. The filing does not provide…
- NEUTRAL PRESS RELEASENov 2, 2026
BrainsWay announced a strategic collaboration with Mindful Health Solutions (MHS), whose managed…
The collaboration is non-exclusive and lacks disclosed financial terms, so near-term revenue impact is uncertain. Monitor for any future revenue-sharing agreements or expansion of the Radial Health…
All BWAY filing & press-release reports (24)
- 6-K reportNov 10, 2026
- 6-K reportNov 10, 2026
- PRESS-RELEASE reportNov 2, 2026
- 6-K reportNov 2, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 21, 2026
- 6-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- 6-K reportOct 13, 2026
- 6-K reportSep 8, 2026
- 6-K reportAug 27, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- 6-K reportJul 20, 2026
- 6-K reportJul 16, 2026
- 6-K reportJun 22, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 13, 2026
- PRESS-RELEASE reportMar 26, 2026
- 6-K reportMar 26, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 4, 2026